ALKS
HEALTHCAREAlkermes plc
$35.32-0.93 (-2.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ALKS Today?
No stock-specific AI insight has been generated for ALKS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$25.17$36.60
$35.32
Fundamentals
Market Cap$5.9B
P/E Ratio39.2
EPS$0.90
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding166.7M
ALKS News
20 articles- Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC SaysYahoo Finance·May 6, 2026
- Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock RisesYahoo Finance·May 6, 2026
- Alkermes plc Q1 2026 Earnings Call SummaryMoby·May 5, 2026
- Alkermes (ALKS) Q1 2026 Earnings TranscriptMotley Fool·May 5, 2026
- Alkermes Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 5, 2026
- Alkermes (ALKS) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Alkermes plc Reports First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YYahoo Finance·May 1, 2026
- Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseYahoo Finance·Apr 29, 2026
- Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to DeclineYahoo Finance·Apr 28, 2026
- Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to TradeYahoo Finance·Apr 28, 2026
- Did New Alixorexton Data and LYBALVI Outcomes Just Shift Alkermes' (ALKS) Neuroscience Investment Narrative?Yahoo Finance·Apr 26, 2026
- Do Options Traders Know Something About Alkermes Stock We Don't?Yahoo Finance·Apr 23, 2026
- Alkermes to Report First Quarter Financial Results on May 5, 2026Yahoo Finance·Apr 21, 2026
- Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual MeetingYahoo Finance·Apr 16, 2026
- Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical PsychiatryYahoo Finance·Apr 14, 2026
- Preparation is key to understanding global trade compliance for trialsClinicaltrialsarena·Apr 13, 2026
- Alkermes Starts Phase 3 Orexin Trials As Narcolepsy Story BuildsYahoo Finance·Apr 2, 2026
- These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target247 Wall St·Apr 1, 2026
All 20 articles loaded
Price Data
Open$35.25
Previous Close$36.25
Day High$36.56
Day Low$34.07
52 Week High$36.60
52 Week Low$25.17
52-Week Range
$25.17$36.60
$35.32
Fundamentals
Market Cap$5.9B
P/E Ratio39.2
EPS$0.90
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding166.7M
About Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—